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The most common type of primary intracranial tumours in man
are gliomas (Russell and Rubenstein, 1989). These tumours are
characterized by their high invasive potential and display a wide
diversity of histological appearances. Even low-grade gliomas
infiltrate the contiguous brain; a key feature which precludes their
successful therapy.
The underlying molecular mechanisms of brain tumour inva-
siveness are complex and involve a series of sequential steps,
including modification of adhesive properties of tumour cells,
degradation and remodelling of extracellular matrix (ECM)
components by proteases such as matrix metalloproteinases
(MMPs or matrixins) and migration of the tumour cells into the
modified region (Liotta, 1986). It is possible that each of these
steps may be modulated by a variety of interactive factors
(Yamada, 1983).
MMPs are a superfamily of zinc-dependent endopeptidases
which cooperatively degrade all components of the ECM. There
are now at least 17 structurally related members in this family
which are either secreted or membrane-bound. The family
includes five subclasses: collagenases, gelatinases, stromelysins,
metalloelastase and membrane-type metalloproteinases (MT-
MMPs). MMPs have been implicated in various physiological and
pathological conditions such as normal embryogenesis and tissue
morphogenesis as well as tumour cell invasion and metastasis
(Woessner, 1991; Romanic and Madri, 1994). Emerging literature
suggests that brain tumour cell invasion utilizes numerous
proteases in vitro, of which the predominant ones may be
gelatinase-A and -B (MMP-2 and -9 respectively) (Rooprai and
McCormick, 1997). As might be expected of enzymes with such
degradative potential, the final in vivo level of activity of MMPs is
tightly controlled and is thought to result from the interactions of
many factors at different levels. It is well documented that the
regulation of MMP expression is complex. The synthesis of many
MMPs and their inhibitors, tissue inhibitors of metalloproteinases
(TIMPs) is thought to be regulated by growth factors, cytokines
and hormones.
There is a vast amount of data in vivo which suggests that
stromal cells of other tumours, probably stimulated by growth
factors produced by malignant cells are the sole producers of
MMPs, even when malignant cells are positive for MMPs at the
protein level (McDougall and Matrisian, 1995). Indeed, a
proposed explanation for the differences between in vitro and in
situ levels of MMPs in gliomas (Reubi et al, 1989) is that local
microenvironmental conditions in vitro stimulate such MMP
activity while in vivo these enzymes are produced locally and on
demand in very small quantities (Rooprai and McCormick, 1997).
Similarly, the cell type of origin of MMP expression in gliomas is
probably not only endothelial (known to be migratory during
embryogenesis) but also neoplastic glia. It is debatable whether
endothelial-derived or neoplastic glial-derived MMPs are used in
the diffuse invasive behaviour of gliomas.
Growth factors are mitogens and exert their effects by inter-
acting with particular cell surface receptors. They can also control
migration and invasion. Growth factors such as epidermal growth
factor (EGF), basic fibroblast growth factor (bFGF), platelet-
derived growth factor (PDGF) and transforming growth factor
beta (TGF-b) have all been shown to stimulate human glioma cell
invasion (Finn et al, 1997; Laerum, 1998).
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We have previously shown that there were discrepancies in
MMP expression in a number of gliomas of various histological
grade and malignancy, when comparative analysis was performed
with immunohistochemistry, immunocytochemistry and zymog-
raphy (Rooprai et al, 1998). Although zymography results showed
that MMP-2 was predominantly expressed, corresponding paraffin
sections showed no expression of either MMP-2, -9 or -14 within
tumours. We proposed that these differences may be explained by
the proliferative state of the cells in vitro, the passage number of
the cell lines, presence of various growth factors, gangliosides and
cell adhesion molecules, levels of TIMPs, genetic changes of
glioma cells in vitro and the cellular heterogeneity of gliomas
in vivo. Two of these factors, the influence of gangliosides
(Maidment et al, 1996) and passage number (Rossi et al, 1996)
have been investigated experimentally by our group. The aim of
this study was to assess whether any of a panel of growth factors
known to be expressed by brain tumours influence production of
MMPs by glioma and meningioma cells in vitro.
MATERIALS AND METHODS
Cell cultures
Surgical samples from patients with various types of brain
tumours were obtained from the neurosurgical staff at Kings’
College Hospital, London. Biopsy material was used to establish
five short-term cultures at low passages. All the samples analysed
were diagnosed by a neuropathologist, according to the World
Health Organization criteria (Kleihues et al, 1993). The samples
included one meningioma, one ependymoma, two astrocytomas
(grade III) and one oligoastrocytoma (grade III).
Cells were cultured as monolayers in small plastic culture flasks
(Marathon) at 37°C, 5% carbon dioxide in a standard humidified
incubator. All the cell lines used in this study were at low passages
(less than P5). Cells were initially maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with antibi-
otic–antimycotic (at a final concentration of 100 IU penicillin,
100 mg streptomycin and 0.25 mg of amphotericin per ml) and
10% fetal calf serum (Sigma). This medium was discarded as the
monolayers attained 70% confluence and replaced on sequential
days with media supplemented with 7%, 3% and finally serum-
free media containing one of the following growth factors at
10 ng ml–1: EGF, bFGF, TGF-b1 and TGF-b2 and vascular
endothelial growth factor (VEGF). The working concentration of
10 ng ml–1 was chosen as our group has previously shown this to
be optimum for glioma invasion in vitro (Merzak et al, 1994). All
growth factors were obtained from Sigma as lyophilized powders
and reconstituted in DMEM to give stock solutions of 100 mg ml–1.
The cells were incubated with growth factors under serum-free
conditions for 48 h, the medium was harvested, dialysed against
water for 16 h individually and freeze-dried. The original volumes
of these cell-conditioned medium samples, which served as the
source of matrix metalloproteinases for zymography, were noted.
Zymography
Zymogram analysis was performed by a modification of the
methods of Heussen and Dowdle (1980) and Rucklidge et al
(1990). Briefly, the substrate gelatin (with a final concentration of
1 mg ml–1) was co-polymerized into an 11% acrylamide resolving
gel at the time of gel casting. The freeze-dried samples were
dissolved in Tris buffer containing 30% glycerol, 7.7% sodium
dodecyl sulphate (SDS) and 0.3% bromophenol blue at pH 6.8
(without heating) and aliquots of media equivalent to a standard-
ized number of cells (4800) were used. The samples were loaded
into 5% stacking gel wells and electrophoresed in a Mini Protean
II Dual Cell (Bio-Rad). The samples were not activated before
running which allows the latent and active forms of each enzyme
to be visualized. The gels were immersed in Triton X-100 (2.5% in
water) for 3 h to deactivate the enzymes by removing the SDS.
The enzymes were then reactivated by incubating the gels in a
50 mM Trizma–HCl buffer (pH 7.6) containing 10 mM calcium
chloride (CaCl2) at 37°C overnight. The gels were stained in
0.025% Coomassie blue in methanol:acetic acid:water (10:1:10
v:v:v) for 4 h and destained with methanol:acetic acid:water
(2:1:10 v:v:v) for 24 h to reveal clear bands containing proteolytic
activity on a dark blue background. The bands were identified in
terms of their molecular weights: 92 kDa and 72 kDa, corre-
sponding to MMP-9 and -2 respectively. Proteolytic activity was
evaluated photodensitometrically using an IBAS 200 image
analyser and verification of the MMP status of enzymes detected
was achieved by substituting the 10 mM CaCl2 with an MMP
inhibitor, 1,10-phenanthroline.
RESULTS
Table 1 represents cumulative results for the zymogram analysis of
gelatinase-A and -B expression (MMP-2 and -9 respectively) in
five cell lines derived from human brain tumour, under the influ-
ence of five exogenous growth factors. Each row represents a cell
line and each column represents MMP-2 and MMP-9 expression
in the presence of various growth factors, compared to the
Table 1 Cumulative results for MMP-2 and -9 expression in five cell lines under the influence of five exogenous growth factors in vitro
Growth factors Control EGF bFGF TGF-b1 TGF-b2 VEGF
MMPs 2 9 2 9 2 9 2 9 2 9 2 9
IPRPE-M P P – – – – + – + – – –
IPMA-E P P + DB – + DB ++ + ++ + ++ – +
IPMC-A3 P (DB) P + DB ++ + DB ++ ++DB + +++DB + +DB +
IPHAB-A3 P (DB) P + DB ++ + DB + + DB ++ + DB ++ + DB ++
IPAB-AO3 P A ++DB ++ ++DB + +++DB + ++ + ++DB +
P = Presence of enzyme, A = absence of enzyme, DB = doublet (both active and latent forms of MMP present); + = up-regulation of MMP secretion,
– = down-regulation of MMP secretion. Growth factors: EGF = epidermal growth factor, bFGF = basic fibroblast growth factor, TGFb = transforming growth
factor, VEGF = vascular endothelial growth factor. Cell lines: IPRPE-M = meningioma, IPMA-E = ependymoma, IPMC-A3 and IPHAB-A3 = Grade 3
astrocytomas, IPAB-AO3 = Grade 3 oligoastrocytoma.54 HK Rooprai et al
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controls. The presence or absence of each enzyme in the controls is
indicated by + and – respectively, whereas its up-regulation is indi-
cated by + and down-regulation by –. The presence of doublets
(DB) implies that the enzyme is present in both the active and
latent forms. Figure 1 represents a typical gel obtained by zymo-
gram analysis. The intensity of the clear bands on the dark back-
ground is proportional to the proteolytic activity. This is also
indicated by ++ or +++ in the table.
The results showed that the effects of the exogenous growth
factors depended upon the cell line used in the study. All the
growth factors generally upregulated both MMP-2 and MMP-9
secretion in the ependymoma and three grade 3 astrocytomas
while downregulation of MMP-2 and -9 was seen in the menin-
gioma (IPRPE-M) under the influence of all the growth factors,
with only two exceptions (Table 1). In the case of the ependymoma
(IPMA-E), down-regulation was seen in MMP-9 with EGF and in
MMP-2 with VEGF. Interestingly, the effects on up-regulation of
MMP secretion were most prominent with TGF-b1 and TGF-b2 in
all the cell lines studied.
DISCUSSION
The results indicate that the exogenous growth factors investigated
are capable of regulating the secretion of MMP-2 and -9 by human
brain tumours in vitro. The most effective stimulators of the
MMPs were TGF-b1 and TGF-b2. To date, there have been
limited reports in the literature on the effects of exogenous growth
factors on MMP expression. However, the findings in the present
study substantiate previous work by other groups who have
reported that TGF-b1 up-regulates these MMPs in cultured human
karatinocytes (Salo et al, 1991) and human fibroblasts (Overall et
al, 1991). The possibility that TGF-b1 can also up-regulate other
MMPs in gliomas has previously been investigated by Nakano
et al (1993) who reported that in two out of four glioma cell lines,
this growth factor up-regulated matrilysin (MMP-7) expression.
The present study also indicates that MMP-2 expression is up-
regulated by VEGF, a finding which is consistent with that of
Lamoreaux et al (1998) who reported that VEGF up-regulates
MMP-2 (and down-regulates TIMPs-1 and -2) in microvascular
endothelial cells. A very recent report (Tamaki et al, 1998)
suggests that C6 astrocytoma cells appear to have a dual regulatory
mechanism for MMP-2 expression which are dependent on cell
density. At low density, these cells respond to bFGF and VEGF by
up-regulating MMP-2 activity, whereas at high density MMP-2 is
down-regulated by released ECM molecules in response to the two
growth factors. The authors suggested that these regulatory mech-
anisms may play a role in the coordination of tumour-associated
angiogenesis by malignant glial cells.
A number of previous studies have clearly shown that growth
factors (EGF, bFGF, PDGF and TGF-b) stimulate human glioma
cell invasion (Engebraaten et al, 1993; Lund-Johansen et al, 1990,
1992; Pedersen et al, 1994). In particular, TGF-b1 acts primarily
as a growth inhibitor (Heldin and Westermark, 1989). Moreover,
our group has shown that TGF-b1 has a dual effect on glioma
cells. In one study, it had a growth inhibitory effect in vitro both on
human fetal astrocytes and three cell lines derived from human
gliomas of different histological type and grade of malignancy
while it is strongly induced stimulation of migration and invasion
by the same cell lines into Matrigel (Merzak et al, 1994). In
another study, different concentrations and different combinations
of growth factors gave varied responses with respect to prolifera-
tion and invasion of gliomas in vitro suggesting synergism–antag-
onism between growth factors. Indeed, both negative and positive
effects of TGF-b1 on the mitogenic actions of EGF, PDGF and
bFGF were seen on a pilocytic astrocytoma cell line (Merzak et al,
1995) while only a negative effect was reported on the mitogenic
action of these other growth factors on malignant glioma cell lines,
except when it was combined with bFGF (Merzak et al, 1994).
The mechanisms underlying stimulation of glioma invasion are
not well understood. It is possible that growth factors may influ-
ence the invasion cascade via ganglioside-mediated ECM adhe-
sion (Pilkington et al, 1993) and also promote invasion by
controlling the balance of ECM protein synthesis and degradation
(Koochekpour et al, 1995). Moreover, the present study indicates
that TGF-b1 can up-regulate MMP-2 and -9 in gliomas, while
earlier reports (Stetler-Stevenson, 1990) showed that tissue
inhibitor of metalloproteinase 2 (TIMP-2) gene expression is
down-regulated in human tumour cell lines by this factor.
Moreover, all isoforms of TGF-b have also been shown to be
abundant at the brain–tumour interface in 64 gliomas, using
immunohistochemical techniques (Merzak et al, submitted).
TGF-b1 was found to be most frequently and TGF-b3 the least
frequently expressed. Both of these growth factors were located in
the centre of the tumour in invasive cells and in endothelial cells.
The three isoforms of TGF-b and the receptor TGF-b type II were
very frequently co-expressed in the tumours suggesting that these
factors may act synergistically in an autocrine manner to promote
glioma progression (Merzak et al, submitted). Further studies
include functional blocking by antibodies to various growth
factors in a larger number of brain tumours as well as investigating
the roles of TGF-b isoforms in the invasive and immunosuppres-
sive behaviour of human gliomas in vitro. It is possible that up-
regulation of MMP expression and invasion of the normal brain by
neoplastic glia may result in response to paracrine growth factors
similar to the mechanisms proposed by Nicholson et al (1994) who
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Figure 1 A representative gel of a zymogram for the grade 3
oligoastrocytoma-derived cell line (IPAB-AO3). The intense 72 kDa
gelatinase (MMP-2) appears as well-defined sets of bands underneath the
less intense 92 kDa (MMP-9) bands. Both enzymes can be seen to be
up-regulated by the various growth factors with respect to the controls. The
doublet band configuration is indicative of the presence of both the activated
and latent form of MMP-2. EGF = epidermal growth factor, bFGF = basic
fibroblast growth factor, TGF-b = transforming growth factor beta,
VEGF = vascular endothelial growth factorGrowth factors and MMPs in brain tumours 55
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investigated the effects of neutrophins and transferrins on degrada-
tive enzymes in malignant melanoma cells in the metastatic
cascade.
The precise mode of action of these growth factors in modu-
lating tumour invasion remains unclear, although growth factors
have been shown to regulate MMP secretion, laminin and
hyaluronic acid production, cell surface ganglioside expression
and adhesion molecule function. It can be concluded that all
growth factors used in this study induced MMP-2 and -9 secretion
generally in the gliomas and ependymoma. The meningioma
behaved differently, showing mainly down-regulation of the
MMPs. One possible hypothesis for this observation is that menin-
giomas are not neuro-ectodermal in origin and therefore may be
biologically different. The growth factor receptor status in menin-
giomas is also likely to be different from that in gliomas (Romanic
and Madri, 1994). Alternatively, gliomas and meningiomas may
not express the same type and levels of MMPs. Preliminary data
from one study shows that malignant meningiomas have minimal
expression of MMPs compared to atypical and benign ones
(Rooprai et al, unpublished data). Local microenvironmental
conditions in vitro may involve mechanisms which appear to
stimulate such MMP activity in gliomas. It is also possible that
paracrine growth factors interplay between heterogeneous glioma
cells may play a role in the regulation of MMP secretion at the
brain–tumour interface thereby facilitating invasion on neoplastic
glial cell secreted ECM.
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